Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Also Read: Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA-editing ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The view from CVS on this deal, it was to go 1-o-1 ... Lucas, thank you very much, and Mike, thank you. Thank you, Eli Lilly.

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was ... The results of the head-to-head trial come days after CVS Health's decision to drop Zepbound from some lists of medicines it covers ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.